Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

This study is asking patients being treated with cabozantinib and nivolumab (a combination of targeted therapy and immunotherapy) for advanced kidney cancer to track their own symptoms digitally, to see if this improves their care. **You may be eligible if:** - You are over 18 years old - You have advanced or metastatic clear-cell kidney cancer - You have not had prior systemic treatment for your kidney cancer - Your doctor has already decided to treat you with cabozantinib plus nivolumab as your first treatment **You may NOT be eligible if:** - You are pregnant or planning to become pregnant during treatment - You are breastfeeding - You are not willing to use effective contraception - You have already received systemic treatment for kidney cancer Talk to your doctor to see if this trial is right for you.